end-of-treatment pet-ct clusters predicted with rna-seq

1
End-of-treatment PET-CT clusters predicted with RNA-seq and multiplexed immuno-assay data measured in peripheral blood E Maasdorp, N Chegou, ST Malherbe, G Walzl, GC Tromp and the Catalysis TB-Biomarker Consortium Fig. 1. Hierarchical clustering of the EOT PET-CT variables demonstra�ng the two main clusters A (”cold”) and B (”hot”). The heatmap is annotated with good or poor outcome (failures and recurrences grouped together), recurrence and previous TB episodes. At the top of the annota�ons are barplots showing propor�ons of the annota�on categories. PrevTB: Previous TB. Cavity MSLA SUVmax TGAI 0 0.5 1 A A A B B B Treatment Outcome poor good UE Recurrence no yes PrevTB yes no Fig. 2. ROC curves of the performance of the classifica�on models to detect EOT PET−CT hot cluster membership, coloured by �me point. The models were trained on the whole month 6 data set, and evaluated on the other �me points. Sensi�vity is represented on the y−axis and 1 minus specificity on the x−axis. A: 6−gene score model B: 3−analyte Luminex score model 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 1 − Specificity Sensi�vity Time point Diagnosis Day 7 Month 1 Month 6 A 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 1 − Specificity Sensi�vity Time point Diagnosis Month 1 Month 6 B Background Monitoring of tuberculosis (TB) treatment response relies on month 2 sputum culture, which is a poor predictor of treatment outcome. A be�er biomarker of treatment response is needed. Positron Emission Tomography and Computerised Tomography (PET-CT) provides complementary informa�on to microbiology at end-of-treatment (EOT), but is expensive and not widely available. It would be most prac�cal to replace PET-CT with a blood-based biomarker. We derived PET-CT outcome groups for predic�ve modelling, from quan�ta�ve EOT PET-CT scan variables, as an alterna�ve to microbiological treatment outcome groups, to inves�gate replacing PET-CT with mul�plexed immunoassay data, gene expression data, or both in combina�on. Methods Ninety-nine par�cipants with sputum culture posi�ve TB were followed-up during treatment un�l 2 years a�er treatment comple�on. PET-CT scans, mul�plexed immunoassay (Luminex) and RNA- sequencing data were available at the diagnosis, week 4 and week 24 �me points. Unsupervised hierarchical clustering of selected quan�ta�ve EOT PET-CT variables produced two outcome groups for predic�ve modelling. Par�al least squares classifica�on models were trained through cross-valida�on on the month 6 RNA-seq and Luminex data sets and applied to the other �me points to predict PET-CT cluster membership. Results One PET-CT cluster consisted of 23 par�cipants with a predominantly inflammatory lung picture, and included seven of eight par�cipants who failed treatment. The second consisted of 76 par�cipants with a less inflammatory or resolved lung picture and 88% of these par�cipants displayed durable cure during study follow-up. Both gene expression and Luminex data models could predict cluster membership and achieved cross-valida�on areas-under-the-curve that ranged from 0.74 to 0.90 at all �me points. Combining gene expression and Luminex data in classifica�on models did not improve on the classifica�on accuracy of the separate models. Conclusion At EOT, PET-CT provides complementary informa�on to microbiological treatment outcomes. Gene expression or protein measured in peripheral blood could poten�ally replace PET-CT, but accuracy should be improved and validated in independent data sets.

Upload: others

Post on 14-Nov-2021

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: End-of-treatment PET-CT clusters predicted with RNA-seq

End-of-treatment PET-CT clusters predicted with RNA-seq and multiplexed immuno-assay data measured in peripheral blood E Maasdorp, N Chegou, ST Malherbe, G Walzl, GC Tromp and the Catalysis TB-Biomarker Consortium

Fig. 1. Hierarchical clustering of the EOT PET-CT variables demonstra�ng the two main clusters A (”cold”) and B (”hot”). The heatmap is annotated with good or poor outcome (failures and recurrences grouped together), recurrence and previous TB episodes. At the top of the annota�ons are barplots showing propor�ons of the annota�on categories. PrevTB: Previous TB.

Cavity MSLA SUVmax TGAI

0

0.5

1A A AB B B

Treatment Outcome

poorgoodUE

Recurrence

noyes

PrevTB

yesno

Fig. 2. ROC curves of the performance of the classifica�on models to detect EOT PET−CT hot cluster membership, coloured by �me point. The models were trained on the whole month 6 data set, and evaluated on the other �me points. Sensi�vity is represented on the y−axis and 1 minus specificity on the x−axis.A: 6−gene score modelB: 3−analyte Luminex score model 0.00

0.25

0.50

0.75

1.00

0.00 0.25 0.50 0.75 1.001 − Specificity

Sens

i�vi

ty

Time pointDiagnosisDay 7Month 1Month 6

A

0.00

0.25

0.50

0.75

1.00

0.00 0.25 0.50 0.75 1.001 − Specificity

Sens

i�vi

ty

Time pointDiagnosisMonth 1Month 6

B

BackgroundMonitoring of tuberculosis (TB) treatment response relies on month 2 sputum culture, which isa poor predictor of treatment outcome. A be�er biomarker of treatment response is needed. Positron Emission Tomography and Computerised Tomography (PET-CT) provides complementary informa�on to microbiology at end-of-treatment (EOT), but is expensive and not widely available. It would be most prac�cal to replace PET-CT with a blood-based biomarker. We derived PET-CT outcome groups for predic�ve modelling, from quan�ta�ve EOT PET-CT scan variables, as an alterna�ve to microbiological treatment outcome groups, to inves�gate replacing PET-CT with mul�plexed immunoassay data, gene expression data, or both in combina�on.MethodsNinety-nine par�cipants with sputum culture posi�ve TB were followed-up during treatment un�l 2 years a�er treatment comple�on. PET-CT scans, mul�plexed immunoassay (Luminex) and RNA-sequencing data were available at the diagnosis, week 4 and week 24 �me points. Unsupervised hierarchical clustering of selected quan�ta�ve EOT PET-CT variables produced two outcome groups for predic�ve modelling. Par�al least squares classifica�on models were trained through cross-valida�on on the month 6 RNA-seq and Luminex data sets and applied to the other �me points to predict PET-CT cluster membership.ResultsOne PET-CT cluster consisted of 23 par�cipants with a predominantly inflammatory lung picture, and included seven of eight par�cipants who failed treatment. The second consisted of 76 par�cipants with a less inflammatory or resolved lung picture and 88% of these par�cipants displayed durable cure during study follow-up. Both gene expression and Luminex data models could predict cluster membership and achieved cross-valida�on areas-under-the-curve that ranged from 0.74 to 0.90 at all�me points. Combining gene expression and Luminex data in classifica�on models did not improve on the classifica�on accuracy of the separate models. ConclusionAt EOT, PET-CT provides complementary informa�on to microbiological treatment outcomes. Gene expression or protein measured in peripheral blood could poten�ally replace PET-CT, but accuracy should be improved and validated in independent data sets.